Journal of Clinical Oncology · 2004 · 137 citations · 25 references
MedicineGynecologyOncologyCancer ScreeningEarly DetectionGynecologic OncologyBenign Ovarian TumorsCancer BiomarkersEarly Cancer DetectionOvarian CancerOvarian PathologyTumor MarkersEarly Cancer Detection MarkersOvarian Cancer BiomarkersOvarian Cancer DetectionOvarian Cancer Early DetectionOvarian Cancer Prognostic BiomarkersOvarian Tumor BiomarkersSecreted AntigensSerum Tumor Markers
PURPOSE: YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer. MATERIALS AND METHODS: Serum YKL-40 levels were assayed by enzyme-linked immunosorbent assay for 46 healthy subjects, 61 high-risk individuals, 33 patients with benign gynecologic processes, and 50 preoperative patients subsequently diagnosed with predominantly early-stage ovarian cancer. Serum CA125 and CA15-3 values were obtained. RESULTS: Median YKL-40 level was 28 ng/mL (range, 15 to 166 ng/mL) for healthy subjects, 36 ng/mL (range, 9 to 69 ng/mL) for high-risk individuals without prior cancer, 44.5 ng/mL (range, 5 to 133 ng/mL) for high-risk patients with prior breast cancer, and 38 ng/mL (range, 5 to 67 ng/mL) for individuals with benign gynecologic processes (P = NS). Median preoperative YKL-40 level for ovarian cancer patients was 94 ng/mL (range, 17 to 517 ng/mL; P <.0001 compared with normal and high-risk). YKL-40 was elevated (>/= 62 ng/mL) in 36 (72%) of 50 patients compared with 23 (46%) of 50 and 13 (26%) of 50 patients for CA125 and CA15-3 (P <.008). Twenty (65%) of 31 early-stage patients had elevated serum YKL-40 levels compared with 11 (35%) of 31 and four (13%) of 31 patients for CA125 and CA15-3 (P =.039). YKL-40 levels increased with stage (P <.005), regardless of grade, histology, or patient age. Patients with early-stage tumors with YKL-40 values more than 80 ng/mL had a worse prognosis (71% recurrence v no recurrence [P =.034]). CONCLUSION: YKL-40 may represent a novel marker for the detection of early-stage ovarian cancer. YKL-40 levels in early-stage patients may also predict disease recurrence and survival. The utility of YKL-40 in detection of early-stage ovarian cancer deserves further investigation.
25
Robert T. Greenlee, M. B. Hill-Harmon, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2001 · 3.3K citations · Full text
Use of proteomic patterns in serum to identify ovarian cancer
Emanuel F. Petricoin, Ali M. Ardekani, Ben A. Hitt et al. · The Lancet · 2002 · 3.3K citations
Medicine, Gynecology, Oncology +17